德尔塔
您当前所在位置:首页 > 定制产品 > 微球/磁珠

CAS:1189703-33-0|Ethosuximide-d3,乙琥胺 d3

发布时间:2025-06-04     作者:德尔塔生物   分享到:

【产品介绍】:

生物活性:Ethosuximide-d3 is the deuterium labeled Ethosuximide. Ethosuximide, a widely prescribed anti-epileptic agent, improves the phenotypes of multiple neurodegenerative disease models and blocks the low voltage activated T-type calcium channel[1][2].
体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Ethosuximide-d3 相关抗体:
Annexin VI Antibody
Calbindin Antibody
Calreticulin Antibody
Cardiac Troponin I/TNNC1 Antibody
SCGN Antibody (YA1167)
RAMP1 Antibody (YA1818)
Annexin V Antibody (YA1829)
Striatin 4 Antibody (YA2088)
Fibulin 5 Antibody (YA2448)
RASGRP1 Antibody (YA2546)
Fibulin 1 Antibody (YA2831)
EFEMP1 Antibody (YA2883)
CRCP Antibody (YA3350)
Annexin VII Antibody (YA1138)
Parvalbumin Antibody (YA1249)
Annexin IV Antibody (YA1921)
SERCA2 ATPase Antibody (YA1931)
Stromal Interaction Molecule 1 Antibody (YA2092)
SERCA1 ATPase Antibody (YA2157)
TrpV5 Antibody (YA2284)
NCX1 Antibody (YA2331)
Scramblase 1 Antibody (YA2419)
CAB39 Antibody (YA2761)
CUG BP1 Antibody (YA2806)
C10orf63 Antibody (YA2894)
ITPK1 Antibody (YA3125)
ORAI3 Antibody (YA3128)
ORAI1 Antibody (YA3157)
CREB Regulated Transcription Coactivator 2 Antibody (YA3279)
分子量:144.19
Formula:C7H8D3NO2
CAS 号:1189703-33-0
非标记 CAS:77-67-8
性状:固体
颜色:White to off-white
中文名称:乙琥胺 d3
运输条件:Room temperature in continental US; may vary elsewhere.
储存方式:Powder:-20°C:3 years,4°C:2 years
In solvent:-80°C:6 months,-20°C:1 month
纯度 & 产品资料
纯度: ≥99.0%
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]
[2]. Chen X, et al. Ethosuximide ameliorates neurodegenerative disease phenotypes by modulating DAF-16/FOXO target gene expression. Mol Neurodegener. 2015 Sep 29;10:51.
 [Content Brief]
[3]. Sondossi K, et al. Analysis of the antiepileptic, ethosuximide impacts on neurogenesis of rat forebrain stem cells. Fundam Clin Pharmacol. 2014 Oct;28(5):512-8.
 [Content Brief]